385 related articles for article (PubMed ID: 1726206)
1. Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
Geddes AM
Drugs; 1991; 42 Suppl 3():34-40. PubMed ID: 1726206
[TBL] [Abstract][Full Text] [Related]
2. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
Balfour JA; Benfield P
Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
[TBL] [Abstract][Full Text] [Related]
3. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
Fulton B; Perry CM
Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
[TBL] [Abstract][Full Text] [Related]
4. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
Frampton JE; Brogden RN; Langtry HD; Buckley MM
Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
[TBL] [Abstract][Full Text] [Related]
5. Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group.
Klein M
Pediatr Infect Dis J; 1995 Apr; 14(4 Suppl):S19-22. PubMed ID: 7792126
[TBL] [Abstract][Full Text] [Related]
6. Cefpodoxime proxetil in upper respiratory tract infections.
Bergogne-Berezin E
Drugs; 1991; 42 Suppl 3():25-33. PubMed ID: 1726205
[TBL] [Abstract][Full Text] [Related]
7. Cefpodoxime proxetil suspension compared with cefaclor suspension for treatment of acute otitis media in paediatric patients.
MacLoughlin GJ; Barreto DG; de la Torre C; Pinetta EA; del Castillo F; Palma L
J Antimicrob Chemother; 1996 Mar; 37(3):565-73. PubMed ID: 9182113
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with cefpodoxime proxetil in acute otitis media.
Cohen R
Pediatr Infect Dis J; 1995 Apr; 14(4 Suppl):S12-8. PubMed ID: 7792125
[TBL] [Abstract][Full Text] [Related]
9. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections.
Cox CE; Graveline JF; Luongo JM
Drugs; 1991; 42 Suppl 3():41-50. PubMed ID: 1726207
[TBL] [Abstract][Full Text] [Related]
10. Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections.
Safran C
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():93-101. PubMed ID: 2292535
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis.
Periti P; Novelli A; Schildwachter G; Schmidt-Gayk H; Ryo Y; Zuck P
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():63-9. PubMed ID: 2292532
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acute maxillary sinusitis--comparing cefpodoxime proxetil with amoxicillin.
von Sydow C; Savolainen S; Söderqvist A
Scand J Infect Dis; 1995; 27(3):229-34. PubMed ID: 8539546
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens.
Owens RC; Tessier P; Nightingale CH; Ambrose PG; Quintiliani R; Nicolau DP
Int J Antimicrob Agents; 2001 Jun; 17(6):483-9. PubMed ID: 11397619
[TBL] [Abstract][Full Text] [Related]
16. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
Lode H
Dtsch Med Wochenschr; 1999 Dec; 124(48):1459-61. PubMed ID: 10615328
[No Abstract] [Full Text] [Related]
17. [Clinical and bacteriological studies of ceftriaxone (CTRX) once daily administration in pediatric patients with respiratory tract infections].
Hasui M; Kobayashi Y; Harada Y; Ono A; Okazaki H; Kino M; Hara T
Jpn J Antibiot; 2001 Oct; 54(10):532-40. PubMed ID: 11771335
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetic, bacteriological and clinical studies on cefpodoxime proxetil in the field of pediatrics].
Akita H; Sato Y; Iwata S; Sunakawa K
Jpn J Antibiot; 1989 Jul; 42(7):1547-60. PubMed ID: 2810729
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections.
Dabernat H; Avril JL; Boussougant Y
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():1-6. PubMed ID: 2127267
[TBL] [Abstract][Full Text] [Related]
20. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections.
Hoepelman AI; Sips AP; van Helmond JL; van Barneveld PW; Neve AJ; Zwinkels M; Rozenberg-Arska M; Verhoef J
J Antimicrob Chemother; 1993 Jun; 31 Suppl E():147-52. PubMed ID: 8396086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
